reports
Shareholding declaration Valneva SE - January 2025
Shareholding declaration Valneva SE - January 2025 VALNEVA Declaration of shares and voting rights January 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: February 6, 2025 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized To...
- Oscar Haffen Lamm
Valneva: Ixchiq approved in the UK
Valneva’s Chikungunya vaccine, Ixchiq, has received marketing authorization from the MHRA and is set to enter the UK market for individuals aged 18 and older. While this approval was anticipated, the UK’s traveller market will now complement the EU4, where the vaccine has been approved since last J
Valneva Receives Marketing Authorization in the UK for the World’s Fir...
Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ® Saint Herblain (France), February 5, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for the world’s first and only chikungunya vaccine, IXCHIQ®. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older. The vac...
Valneva reçoit une autorisation de mise sur le marché au Royaume-Uni p...
Valneva reçoit une autorisation de mise sur le marché au Royaume-Uni pour le premier vaccin au monde contre le chikungunya, IXCHIQ® Saint Herblain (France), le 5 février 2025 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que l’autorité de santé britannique Medicines and Healthcare products Regulatory Agency (MHRA) a accordé une autorisation de mise sur le marché au Royaume-Uni à IXCHIQ®, le premier et le seul vaccin au monde contre le chikungunya. Le vaccin à dose unique de Valneva est indiqué pour une immunisation active pour la prévent...
- Jean-François Granjon
- Louis Boujard
- CFA
- Thomas Zlowodzki
CGM CEGEDIM SA
VETO VETOQUINOL SA
KOF KAUFMAN & BROAD SA
ALLAN LANSON-BCC
ALCAR CARMAT SA
BAMNB KONINKLIJKE BAM GROEP NV
ELIS ELIS SA
GNFT GENFIT SA
SEFER SERGEFERRARI GROUP SA
SSO SCATEC ASA
RBO ROCHE BOBOIS INTERNATIONAL SAS
WAVE WAVESTONE SA
SFQ SAF-HOLLAND SE
ALHRS HYDROGEN REFUELING SOLUTIONS
LHYFE LHYFE S.A.
- Andreas Riemann
- Jean Danjou
- Thomas Zlowodzki
CGM CEGEDIM SA
VETO VETOQUINOL SA
KOF KAUFMAN & BROAD SA
ALLAN LANSON-BCC
ALCAR CARMAT SA
BAMNB KONINKLIJKE BAM GROEP NV
ELIS ELIS SA
GNFT GENFIT SA
SEFER SERGEFERRARI GROUP SA
SSO SCATEC ASA
RBO ROCHE BOBOIS INTERNATIONAL SAS
WAVE WAVESTONE SA
SFQ SAF-HOLLAND SE
ALHRS HYDROGEN REFUELING SOLUTIONS
MRX MISTER SPEX SE
LHYFE LHYFE S.A.
- Carole Braudeau
- Carole Braudeau
- Jean-François Granjon
- Louis Boujard
- CFA
- Jean-François Granjon
- Louis Boujard
- CFA
- Oscar Haffen Lamm
Valneva: Renewed USD32.8m DoD contract for Ixiaro
Valneva announced the signing of a new USD32.8m contract with the DoD for the supply of Ixiaro, with the possibility to purchase additional doses during the coming 12 months. While largely expected considering the long-term relationship the company has with the DoD, we nonetheless welcome this news
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Lhyfe: FY24 review, new subsidies in Sweden
Today Lhyfe released its FY24 activity report. In line with the guidance update in September, FY24 revenue reached EUR5.1m (+20% vs cons. at EUR5m) and installed capacity topped 22MW (vs guidance for >20MW). With a total pipeline of 9.1GW and 558MW in advanced development (vs 9.5GW and 598MW in
Ipsos becomes the leader of social and government research in Australi...
Ipsos becomes the leader of social and government research in Australia with the acquisition of Whereto Research Ipsos becomes the leader of social and government research in Australia with the acquisition of Whereto Research Paris, 30 January 2025 - , one of the world’s leading market research companies, announces the acquisition of Whereto Research, a key player in public sector research in Australia. Based primarily in Melbourne, Whereto Research is renowned for its expertise in public policies and government communication evaluation. Ipsos has been operating in Australia since more t...
Valneva Announces New IXIARO® Supply Contract with the U.S. Government...
Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million Saint Herblain (France), January 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32.8 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®.Under this new one-year contract, the DoD will buy a minimum of $32.8 million worth of IXIARO® vaccines and has the possibility to purchase additional doses during the coming twelve month...
Half-year report on IPSOS’ liquidity contract - December 2024
Half-year report on IPSOS’ liquidity contract - December 2024 January 28, 2025 Half-year report on IPSOS’ liquidity contract with Exane BNP PARIBAS Under the liquidity contract entrusted by IPSOS SA to Exane BNP Paribas, the following assets appeared on the liquidity account as at December 31, 2024: 24,859 IPSOS shares (transactions pending completion)€425,871 During the 2nd half 2024, it has been traded a total of: Purchase85,882 shares€4,591,737970 transactionsSale81,783 shares€4,399,216861 transactions For information, the follo...
Ipsos: Disclosure of trading in own shares under a share buyback progr...
Ipsos: Disclosure of trading in own shares under a share buyback programme (21 to 24 January 2025) 28 January 2025 Disclosure of trading in own shares under a share buyback programme Period : From 21 to 24 January 2025 Issuer’s registered name: Ipsos Issuer’s Identification code: 9695002OY2X35E9X8W87 Financial instrument reference: Ordinary shares – ISIN code FR0000073298 Reporting of transactions in aggregated form (per day and per trading venue) Issuer name Issuer Code Transaction date ISIN Code Daily total volume (in number of shares) Daily weighted average price ...
Ipsos: Monthly declaration of shares and voting rights - December 2024
Ipsos: Monthly declaration of shares and voting rights - December 2024 January 28, 2025 MONTHLY DISCLOSURE OF THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Articles L. 233-8 II of the Commercial Code and 223-16 of the General Regulation of the AMF Date Shares Voting rights Theoretical* Exercisable** 31 December 2024 43,203,225 48,757,604 48,632,135 *This number is calculated on the basis of all the shares to which voting rights are attached, including shares which voting rights have been suspended, in accordance with Article 223-11 of the AMF general regulation ...
Ipsos : Déclaration mensuelle d'actions et de droits de vote - Décembr...
Ipsos : Déclaration mensuelle d'actions et de droits de vote - Décembre 2024 28 janvier 2025 PUBLICATION MENSUELLE DU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE Articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’AMF Date Nombre d’actions composant le capital Nombre total de droits de vote théoriques* exerçables** 31 décembre 2024 43 203 225 48 757 604 48 632 135 * Ce nombre est calculé sur la base de l’ensemble des actions auxquelles sont attachés des droits de vote, y compris les actions privées de droit de vote, conf...
- Oscar Haffen Lamm
Valneva: Ixchiq proven safe in children in phase 2 trial
Valneva announced positive results for its phase 2 trial evaluating the safety and immunogenicity of two different dose levels (full dose and half dose) of Ixchiq in 304 children (aged 1-11 y.o.), meeting its primary endpoint and demonstrating that the vaccine was well tolerated, regardless of the
Valneva Reports Positive Phase 2 Results in Children for its Chikungun...
Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision Saint-Herblain (France), January 22, 2025 – (Nasdaq: VALN; Euronext Paris: VLA) today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children. Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial is intended to support a pivotal Phase 3 study in children, which the C...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.